The leukocyte adhesion deficiency management global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Leukocyte Adhesion Deficiency Management Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $7.48 billion in 2023 to $8.07 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increased awareness and education, genetic testing advancements, orphan drug designations, global health policies, patient advocacy groups, pediatric healthcare advancements..
The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of novel therapeutics, expanded genetic testing accessibility, patient-centric drug development, advancements in immunomodulatory therapies.. Major trends in the forecast period include stem cell transplantation innovations, integration of supportive therapies, telemedicine for remote consultations, collaboration and research networks, integration of biomarker technologies..
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/leukocyte-adhesion-deficiency-management-global-market-report
Scope Of Leukocyte Adhesion Deficiency Management Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Leukocyte Adhesion Deficiency Management Market Overview
Market Drivers –
The rising prevalence of primary immunodeficiency is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Primary immunodeficiency (PID) is a group of inherited disorders that weaken the body’s immune system, making individuals more susceptible to infections and illnesses due to defects in their immune responses. Management of leukocyte adhesion deficiency benefits primary immunodeficiency by advancing the understanding of immune system disorders and potentially leading to improved diagnostic tools and therapies to help both conditions. For instance, in April 2023, according to the Peace Hospital, an India-based multi-specialty hospital, the data collected from World Primary Immunodeficiency (WPI) Awareness Week 2023 shows that primary immunodeficiency (PI) affects an estimated 60 lakh people globally, and 70% to 90% of people have undiagnosed primary immunodeficiency. Therefore, the rising prevalence of primary immunodeficiency will drive the growth of the leukocyte adhesion deficiency management market.
Market Trends –
Major companies operating in the leukocyte adhesion deficiency management market are focused on developing novel treatments and therapies, such as RP-L201, to address the underlying genetic defects and improve the quality of life for affected individuals. Regenerative Medicine Advanced Therapy (RMAT) for RP-L201 supports the efficient development of advanced gene therapy for treating leukocyte adhesion deficiency-I (LAD-I). For instance, in March 2021, Rocket Pharmaceuticals, Inc., a US-based clinical-stage company, received the U.S. Food and Drug Administration (FDA) designation for Regenerative Medicine Advanced Therapy (RMAT) (RP-L201). The RMAT designation was obtained based on promising preliminary safety and efficacy data from RP-L201’s ongoing Phase 1/2 clinical trial. The RMAT designation was created to aid in developing and approving regenerative medicine products such as cell and gene therapies. The designation is given to an investigational product that has the potential to treat, alter, reverse, or cure a serious or life-threatening disease or condition and is supported by preliminary clinical evidence demonstrating its ability to address an unmet medical need.
The leukocyte adhesion deficiency management market covered in this report is segmented –
1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors
2) By Diagnosis: Blood Test, Genetic Testing, Biopsy, Other Types
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Get an inside scoop of the leukocyte adhesion deficiency management market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13172&type=smp
Regional Insights –
North America was the largest region in the leukocyte adhesion deficiency management market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.
Table of Contents
1. Executive Summary
2. Leukocyte Adhesion Deficiency Management Market Report Structure
3. Leukocyte Adhesion Deficiency Management Market Trends And Strategies
4. Leukocyte Adhesion Deficiency Management Market – Macro Economic Scenario
5. Leukocyte Adhesion Deficiency Management Market Size And Growth
…..
27. Leukocyte Adhesion Deficiency Management Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
